The balloon catheters market has seen considerable growth due to a variety of factors.
• In the recent past, the market size for balloon catheters has seen a sturdy growth. It is projected to increase from $3.92 billion in 2024 to $4.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.6%.
The growth experienced in the historic period is due to several reasons including the heightened attention on management of chronic diseases, a rise in cardiovascular disease cases, a growing emphasis on patient-centered healthcare, an aging population, and a burgeoning demand for improved catheter performance.
The balloon catheters market is expected to maintain its strong growth trajectory in upcoming years.
• The market for balloon catheters is projected to witness substantial expansion in the forthcoming years, expected to reach $5.08 billion by 2029, with a compound annual growth rate (CAGR) of 5.3%.
This anticipated growth during the forecast period can be linked to factors such as an uptick in healthcare expenditure, emergence of endovascular procedures, escalated research and development efforts, increased utilization of balloon catheters in areas outside of cardiovascular application, and better healthcare provisions in developing markets. The forecast period is also expected to reveal trends like stent placement facilitated by balloons, refined inflation mechanisms, personalized solutions utilizing advanced imaging, and synergy with wearable technology and remote monitoring devices.
As the adoption rate of minimally invasive surgical procedures rises, so does the expansion of the balloon catheters market. Minimally invasive surgeries, which encompass a range of operations conducted with minor incisions, limit the requirement for substantial cuts or body openings. These types of surgeries have seen a rise in popularity due to decreased recovery periods, a lesser probability of complications, and lesser pain due to advancements in technology and outpatient procedures. The crucial role of balloon catheters in boosting the positive impacts of minimally invasive surgeries is undeniable. They elevate the precision, safety, and ease of the procedures while lessening recovery time and duration of hospital stay. An example of this is the placement of 415 da Vinci surgical systems in the fourth quarter of 2023 by US-based robotic products manufacturer, Intuitive Surgical Inc., which reflects a 12% increase compared to 2022. As a result, the continuous rise in the implementation of minimally invasive surgeries stimulates the growth of the Balloon catheters market.
The balloon catheters market covered in this report is segmented –
1) By Type: Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters, Chronic Total Occlusion (CTO) Balloon Catheters, Microcatheters
2) By Product Type: Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, Stent Graft Balloon Catheter, Scoring Balloon Catheter
3) By Distribution Channel: Direct Tender, Third Party Distribution, Other Distribution Channels
4) By Application: Coronary Artery Disease, Peripheral Artery Disease, Other Applications
5) By End User: Hospitals, Specialty Centers, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters: Semi-Compliant Balloon Catheters, Non-Compliant Balloon Catheters
2) By Chronic Total Occlusion (CTO) Balloon Catheters: High-Pressure CTO Balloon Catheters, Low-Profile CTO Balloon Catheters
3) By Microcatheters: Diagnostic Microcatheters, Therapeutic Microcatheters
Leading organizations in the balloon catheters market are concentrating on creating solutions for the mechanical thrombectomy (MT) procedure; thus enhancing blood clot removal efficiency by locally managing blood flow. A minimally invasive technique, MT is commonly employed to extract blood clots from blood vessels, mostly in ischemic stroke incidents. For instance, in September 2024, CERENOVUS, a subsidiary of Johnson & Johnson Medical Devices Companies that specializes in neurovascular medicine, introduced the EMBOGUARD Balloon Guide Catheter in Europe. The device, which is intended for endovascular procedures such as acute ischemic stroke treatment, promotes clot extraction by local blood flow control during MT procedures. Using the EMBOGUARD catheter can potentially increase the rate of successful recanalizations on the first attempt, decrease the duration of the procedure, and minimize the risk of clot fragments triggering distal emboli and subsequent ischemic events. The CERENOVUS Stroke Solutions portfolio, a comprehensive range of technologies to support physicians in executing MT procedures, includes the EMBOGUARD Balloon Guide Catheter.
Major companies operating in the balloon catheters market are include:
• Cardinal Health Inc.
• Johnson & Johnson
• Abbott Laboratories
• Medtronic plc
• Boston Scientific Corporation
• Lepu Medical Technology
• B. Braun Melsungen AG
• Terumo Corporation
• Teleflex Incorporated
• Cook Medical Inc.
• Biotronik SE & Co. KG
• Merit Medical Systems Inc.
• Asahi Intecc Co. Ltd.
• Freudenberg Medical LLC
• Biomerics
• AngioDynamics Inc.
• Endologix Inc.
• Raumedic AG
• Otsuka Pharmaceutical Factory Inc.
• AngioScore Inc.
• CardioFlow
• Endocor GmbH
• MicroPort Scientific Corporation
• Eureka Medical Inc.
• Neovasc Inc.
North America was the largest region in the balloon catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the balloon catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.